|
Jan 12
|
Geron to Participate in the B. Riley Securities Virtual Oncology Conference
|
|
Dec 6
|
Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis
|
|
Dec 4
|
Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS
|
|
Nov 28
|
Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors
|
|
Sep 29
|
Geron Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS
|
|
Sep 12
|
4 big analyst picks: CVS picks up upgrade on 'attractive risk/reward,' per Wolfe
|
|
Sep 11
|
Geron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron's Long-Time Chief Financial Officer
|
|
Sep 7
|
Geron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat in Lower Risk MDS at Society of Hematologic Oncology Annual Meeting
|
|
Jul 20
|
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Apr 28
|
Why Is Bluebird (BLUE) Up 17.2% Since Last Earnings Report?
|
|
Apr 27
|
Why Is Kodiak Sciences Inc. (KOD) Down 26.3% Since Last Earnings Report?
|
|
Feb 13
|
2 Top Healthcare Stocks to Buy Right Now
|
|
Feb 9
|
Geron (GERN) Dips More Than Broader Markets: What You Should Know
|